CN102883743A - 用于制备胰岛素-锌复合物的方法 - Google Patents

用于制备胰岛素-锌复合物的方法 Download PDF

Info

Publication number
CN102883743A
CN102883743A CN201180023303XA CN201180023303A CN102883743A CN 102883743 A CN102883743 A CN 102883743A CN 201180023303X A CN201180023303X A CN 201180023303XA CN 201180023303 A CN201180023303 A CN 201180023303A CN 102883743 A CN102883743 A CN 102883743A
Authority
CN
China
Prior art keywords
insulin
chain
amino acid
cooh
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180023303XA
Other languages
English (en)
Chinese (zh)
Inventor
L.安德烈森
R.R.E.汉森
P.杰佩森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201611166272.4A priority Critical patent/CN107029212A/zh
Publication of CN102883743A publication Critical patent/CN102883743A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201180023303XA 2010-05-10 2011-05-09 用于制备胰岛素-锌复合物的方法 Pending CN102883743A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611166272.4A CN107029212A (zh) 2010-05-10 2011-05-09 用于制备胰岛素‑锌复合物的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10162368 2010-05-10
EP10162368.4 2010-05-10
US33349710P 2010-05-11 2010-05-11
US61/333497 2010-05-11
PCT/EP2011/057388 WO2011141407A1 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611166272.4A Division CN107029212A (zh) 2010-05-10 2011-05-09 用于制备胰岛素‑锌复合物的方法

Publications (1)

Publication Number Publication Date
CN102883743A true CN102883743A (zh) 2013-01-16

Family

ID=42732779

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611166272.4A Pending CN107029212A (zh) 2010-05-10 2011-05-09 用于制备胰岛素‑锌复合物的方法
CN201180023303XA Pending CN102883743A (zh) 2010-05-10 2011-05-09 用于制备胰岛素-锌复合物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611166272.4A Pending CN107029212A (zh) 2010-05-10 2011-05-09 用于制备胰岛素‑锌复合物的方法

Country Status (12)

Country Link
US (5) US20130143803A1 (enExample)
EP (1) EP2569002B1 (enExample)
JP (2) JP6249773B2 (enExample)
KR (2) KR20130092972A (enExample)
CN (2) CN107029212A (enExample)
AU (1) AU2011252127B2 (enExample)
BR (1) BR112012028766A2 (enExample)
CA (1) CA2795091A1 (enExample)
ES (1) ES2612468T3 (enExample)
MX (1) MX2012012943A (enExample)
RU (1) RU2572214C2 (enExample)
WO (1) WO2011141407A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149245A1 (zh) * 2018-02-01 2019-08-08 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
CN111565710A (zh) * 2017-12-07 2020-08-21 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
US12186373B2 (en) 2017-12-07 2025-01-07 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105636979B (zh) * 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
BR112021011156A2 (pt) 2018-12-11 2021-10-26 Sanofi Conjugados de insulina
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133598A (zh) * 1993-09-17 1996-10-16 诺沃挪第克公司 酰化的胰岛素
CN101389650A (zh) * 2005-12-28 2009-03-18 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) * 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP2264066A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133598A (zh) * 1993-09-17 1996-10-16 诺沃挪第克公司 酰化的胰岛素
CN101389650A (zh) * 2005-12-28 2009-03-18 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565710A (zh) * 2017-12-07 2020-08-21 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
US12186373B2 (en) 2017-12-07 2025-01-07 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
WO2019149245A1 (zh) * 2018-02-01 2019-08-08 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法

Also Published As

Publication number Publication date
BR112012028766A2 (pt) 2017-06-13
KR20130092972A (ko) 2013-08-21
EP2569002B1 (en) 2016-10-26
US20150250857A1 (en) 2015-09-10
ES2612468T3 (es) 2017-05-17
AU2011252127A1 (en) 2012-11-01
US20210060132A1 (en) 2021-03-04
US20170165327A1 (en) 2017-06-15
KR20160105979A (ko) 2016-09-08
RU2012148821A (ru) 2014-06-20
EP2569002A1 (en) 2013-03-20
MX2012012943A (es) 2012-11-29
JP2013526501A (ja) 2013-06-24
US20130143803A1 (en) 2013-06-06
CA2795091A1 (en) 2011-11-17
CN107029212A (zh) 2017-08-11
US20240307503A1 (en) 2024-09-19
JP2017203042A (ja) 2017-11-16
RU2572214C2 (ru) 2015-12-27
AU2011252127B2 (en) 2014-02-20
JP6249773B2 (ja) 2017-12-20
WO2011141407A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
CN102883743A (zh) 用于制备胰岛素-锌复合物的方法
EP3323423B1 (en) Rapid establishment and/or termination of substantial steady-state drug delivery
US9603904B2 (en) Treating diabetes melitus using insulin injections with less than daily injection frequency
EP2157967B1 (en) Suspension formulations of insulinotropic peptides and uses thereof
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
EP2411037B1 (fr) Formulation d'insuline a action rapide
CN103167878A (zh) 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
WO2011085393A1 (en) Stable insulin formulations and methods of making and using thereof
US20180125946A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
WO2016001862A1 (en) Extended release formulations of insulins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130116